Overall survival for oncology drugs approved for genomic indications
Drug approvals for genome-informed indications have been increasing in recent years, but it is unknown how many of them have demonstrated an improvement in overall survival (OS). We assessed the frequency of approved genome-informed drugs demonstrating improvements in OS and progression-free survival (PFS) and whether the frequencies differed by cancer type.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Alyson Haslam, Myung Sun Kim, Vinay Prasad Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology